4.7 Article

Clostridium difficile Mixed Infection and Reinfection

期刊

JOURNAL OF CLINICAL MICROBIOLOGY
卷 50, 期 1, 页码 142-144

出版社

AMER SOC MICROBIOLOGY
DOI: 10.1128/JCM.05177-11

关键词

-

资金

  1. NIHR Biomedical Research Centre, Oxford, United Kingdom
  2. Optimer Pharmaceuticals
  3. bioMerieux
  4. Optimer
  5. Novacta
  6. Pfizer
  7. Summit
  8. Medicines Company
  9. Viropharma
  10. National Institutes of Health Research (NIHR) [DRF-2010-03-40] Funding Source: National Institutes of Health Research (NIHR)
  11. National Institute for Health Research [DRF-2010-03-40, NF-SI-0508-10279] Funding Source: researchfish

向作者/读者索取更多资源

Isolates from consecutive Clostridium difficile infection (CDI) fecal samples underwent multilocus sequence typing. Potential reinfections with different genotypes were identified in 88/560 (16%) sample pairs taken 1 to 1,414 days (median, 24; interquartile range [IQR], 1 to 52 days) apart; odds of reinfection increased by 58% for every doubling of time between samples. Of 109 sample pairs taken on the same day, 3 (3%) had different genotypes. Considering samples 0 to 7 days apart as the same CDI, 7% of cases had mixed infections with > 1 genotype.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据